Bladder cancer patients may avoid surgery with new drug combo

NCT ID NCT07322263

Recruiting now Disease control Sponsor: Michael A. O'Donnell Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder can treat high-risk bladder cancer that did not respond to standard BCG therapy. About 174 adults will receive weekly treatments for 6 weeks, then monthly for up to 2 years if the cancer responds. The goal is to see if this approach can control the cancer and offer an alternative to bladder removal surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gemcitabine and Docetaxel (chemotherapy drugs given directly into the bladder)
What this could lead to: If successful, this could offer a bladder-sparing treatment option for people whose bladder cancer did not respond to standard BCG therapy, potentially avoiding the need for bladder removal surgery.
What could go wrong: This is a phase 2 trial with 174 participants, so results are still preliminary. The treatment may not work for everyone, and side effects from the chemotherapy drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BCG-REFRACTORY BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder carcinoma in situ bladder papillary urothelial carcinoma in situ carcinoma micropapillary variant infiltrating bladder urothelial carcinoma non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms refractory malignant neoplasm superficial urinary bladder carcinoma transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BCG-REFRACTORY BLADDER CANCER BCG-UNRESPONSIVE BLADDER CANCER BLADDER CANCER CARCINOMA IN SITU (CIS) HIGH-GRADE PAPILLARY BLADDER TUMORS HIGH-RISK NMIBC MICROPAPILLARY VARIANT UROTHELIAL CARCINOMA (FAVORABLE SUBTYPE) NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) T1 STAGE BLADDER CANCER TA STAGE BLADDER CANCER UROTHELIAL CARCINOMA

Bladder cancer patients may avoid surgery with new drug combo

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions